Swiatek is now the youngest player to reach 10 WTA level finals on clay since Swiss Martina Hingis in 2000
tennis9 hours ago
Pfizer Inc said on Tuesday it is seeking US authorization of its experimental antiviral Covid-19 pill that cut the chance of hospitalization or death for adults at risk of severe disease by 89 per cent in a clinical trial.
Pfizer said it completed submission of its application for emergency use authorisation (EUA) of the drug, Paxlovid, with the US Food and Drug Administration, including data from the drugmaker's clinical trial.
The oral drug could be a promising new weapon in the fight against the pandemic, as it can be taken as an early at-home treatment to help prevent Covid-19 hospitalizations and deaths. It could also become a important tool in countries and areas with limited access to vaccines or low vaccination rates.
It is not immediately clear when US regulators will rule on Pfizer's application. Merck & Co and Ridgeback Biotherapeutics, which are developing a competing pill, molnupiravir, completed their EUA submission on October 11.
A panel of outside advisers to the FDA will meet to consider that application on November 30. It is expected to be available this year.
"We are moving as quickly as possible in our effort to get this potential treatment into the hands of patients, and we look forward to working with the US FDA on its review of our application, along with other regulatory agencies around the world," Pfizer Chief Executive Albert Bourla said in a news release.
A Pfizer spokesperson said that the data the company is submitting came from testing the medicine on unvaccinated, high-risk participants. The FDA will make the final decision on who the drug will be indicated for and how it can be used.
The New York-based drugmaker said it has begun the process of seeking authorization of the treatment in several countries including the United Kingdom, Australia, New Zealand and South Korea, and plans further international submissions.
ALSO READ:
Pfizer has said it expects to manufacture 180,000 treatment courses by the end of next month and at least 50 million courses by the end of 2022.
The company earlier on Tuesday said it will allow generic manufacturers to supply its Covid-19 pill to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP).
Swiatek is now the youngest player to reach 10 WTA level finals on clay since Swiss Martina Hingis in 2000
tennis9 hours ago
Spearheaded by Tunisian Lazzez, 971 Fighting Championship is a unique and innovative MMA entertainment brand
sports9 hours ago
Needing two off the final ball, Rajasthan's Rovman Powell missed a full toss and was trapped in front of the wicket by Bhuvneshwar Kumar
cricket10 hours ago
In the video, Pushpa Raj a.k.a Allu Arjun dances in style with a glass of tea in one hand
entertainment11 hours ago
Not only Alia and Priyanka but Ananya Panday also shared her views on the film
entertainment11 hours ago
Discover exciting activities happening this weekend in the country
entertainment11 hours ago
Blunt recounted how Swift praised Hazel's unique style
entertainment11 hours ago
The sequel to the 2021 movie is an average thriller
movie reviews11 hours ago